PARD on watch for possible takeover by BMY-Poniard Pharmaceuticals To Present at Three Upcoming Investor Conferences in September
29 minutes ago - Pr Newswire
Related Companies
Symbol Last %Chg
PARD 8.13 0.00%
As of 12:00 AM ET 9/1/09
Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on innovative oncology therapies, today announced that Jerry McMahon, Ph.D., chairman and chief executive officer, is scheduled to provide a corporate overview, including a discussion about the clinical development program for the Company's lead product candidate, picoplatin, at three upcoming investor conferences:
-- Baird Healthcare Conference
-- Wednesday, September 9, 2009 at 1:15 p.m. Eastern Time
-- Four Seasons Hotel in New York City
-- Rodman & Renshaw 11th Annual Healthcare Conference
-- Thursday, September 10, 2009 at 10:25 a.m. Eastern Time
-- The Palace Hotel in New York City
-- NewsMakers in the Biotech Industry Conference
-- Wednesday, September 16, 2009 at 11:30 a.m. Eastern Time
-- Millennium Broadway Hotel in New York City
Live audio web casts of Poniard's presentations will be available for 10 business days on the "Events" page of the "News & Events" section of the Company's Web site at poniard.com.
About Poniard Pharmaceuticals
Poniard Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative oncology products to impact the lives of people with cancer. Picoplatin, the Company's lead platform product candidate, is a new generation platinum chemotherapy. To date, clinical studies suggest that picoplatin has an improved safety profile relative to existing platinum-based cancer therapies. Picoplatin is designed to overcome platinum resistance associated with chemotherapy in solid tumors, and is being studied in multiple cancer indications, combinations and formulations. Clinical trials of intravenous picoplatin include a Phase 3 trial in small cell lung cancer and Phase 2 trials in metastatic colorectal and castration-resistant (hormone refractory) prostate cancers. The Company also is conducting a clinical trial of oral picoplatin in solid tumors. For additional information please visit poniard.com.
(C) 2009 Poniard Pharmaceuticals, Inc. All Rights Reserved.
Poniard and Poniard Pharmaceuticals are trademarks of Poniard Pharmaceuticals, Inc.
SOURCE Poniard Pharmaceuticals, Inc.
poniard.com |
